SCHEMBL14712898

SCHEMBL14712898

CCN1C(=O)NC(=O)/C(=C\C=C\c2cccc(Cl)c2)C1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.55
KMT2A Q03164 12/20 0.55
MEN1 O00255 11/20 0.55
MAPK1 P28482 8/20 0.55
ALDH1A1 P00352 8/20 0.55
MITF O75030 5/20 0.55
PKM P14618 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPSR1 Q6W5P4 7/20 0.49
NTSR1 P30989 2/20 0.49
MDM2 Q00987 2/20 0.49
POLB P06746 5/20 0.47
L3MBTL1 Q9Y468 5/20 0.47
KDM4E B2RXH2 4/20 0.47
LMNA P02545 2/20 0.47
RECQL P46063 5/20 0.45
HTT P42858 3/20 0.45
BLM P54132 2/20 0.45
APEX1 P27695 2/20 0.43
TDP1 Q9NUW8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14713004 0.87 KMT2A (0.56) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14712892 0.86 MAPT (0.72) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14713023 0.85 MAPT (0.52) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14712960 0.82 MAPT (0.57) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14712900 0.80 MAPT (0.56) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14713066 0.79 MEN1 (0.64) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14712894 0.77 METAP1 (0.69) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14713002 0.77 MEN1 (0.48) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14712899 0.77 MAPT (0.56) MAPTKMT2AMEN1MAPK1ALDH1A1
SCHEMBL14712877 0.77 MAPT (0.64) MAPTKMT2AMEN1MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MAPT 2828/4885KMT2A 2749/4885MEN1 2410/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 MAPT 3272/4885KMT2A 3262/4885MEN1 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.